ANDA 78756, held by Teva Pharmaceuticals. Dorzolamide Hydrochloride.
As of Nov 21, 2026, ANDA 78756 (Dorzolamide Hydrochloride), held by Teva Pharmaceuticals, was first approved by FDA on Dec 4, 2008, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 4, 2008 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Dorzolamide HydrochlorideEQ 2% BASE · solution/drops;ophthalmic | Dorzolamide Hydrochloride | Discontinued |
| Sep 24, 2026 | Supplement 9Labeling · Standard review | Approved | None posted |
| Apr 6, 2015 | Supplement 6Labeling · Standard review | Approved | None posted |
| Mar 8, 2013 | Supplement 3Labeling | Approved | None posted |
| Dec 4, 2008 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters